Biochemically targeted therapy of refractory leukemia and myeloid blast crisis of chronic granulocytic leukemia with Tiazofurin, a selective blocker of inosine 5′-phosphate dehydrogenase activity

Anticancer Research

Volumn 16, Issue 6 A, 1996, Pages 3341-3348

  Tricot, Guido ^a,c   Weber, George ^b  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b INDIANA UNIVERSITY   (United States)

^c Division of Hematology   (United States)

Author keywords

Granulocytic leukemia; Refractory leukemia; Targeted therapy; Tiazofurin

Indexed keywords

ALLOPURINOL; GUANOSINE PHOSPHATE; GUANOSINE TRIPHOSPHATE; HYPOXANTHINE; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; OXIDOREDUCTASE; TIAZOFURIN;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL CRISIS; BLOOD LEVEL; BONE MARROW CELL; CHRONIC GRANULOCYTIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; DERMATITIS; DROWSINESS; DRUG MONITORING; DRUG SELECTIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GRANULOCYTE; HEADACHE; HUMAN; HUMAN CELL; HYPERTENSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MYALGIA; NAUSEA; NEUTROPENIA; PERICARDITIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; SEIZURE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BLAST CRISIS; FEMALE; HUMANS; IMP DEHYDROGENASE; LEUKEMIA, MYELOID, CHRONIC; LEUKEMIA, NONLYMPHOCYTIC, ACUTE; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; RIBAVIRIN;

EID: 0030499040     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Pederson-Gjergaard J, Philip P, Larsen SO, Andersson M, Daugaard G, Ersboll J, Hansen SW, Hou-Jensen K, Nielsen D, Sigsgaard TC, Specht L and Osterlind K: Therapy-related myelodysplasia and acute myeloma leukemia. Cytogenetic charaeteristics of 115 consecutive cases and risk in seven cohorts of patients treated intensively for malignant diseases in The Copenhagen Series. Leukemia 7: 1975-1986, 1993.
2. Kergueris MF, Milpied N, Moreau P, Harousseau JL, Larousse C: Pharmacokinetics high-dose melphalan in adults: influence of renal function. Anticancer Res 14: 2379-2382, 1994.
3. Weber G Enzymology of cancer cells. N Engl J Med 296: 486-493, 541-551, 1977.
4. Weber G: Biochemical strategy of cancer cells and the design of chemotherapy. GHA Clowes Memorial Lecture. Cancer Res 43:3466-3492, 1983.
5. Weber G, Prajda N, Jackson RC. Key enzymes of IMP metabolism: transformation- and proliferation-linked alterations in gene expression. Advan Enzyme Regul 14: 3-24, 1976.
6. Robins RK: Nucleoside and nucleotide inhibitors of inosine monophosphate (IMP) dehydrogenase as potential antitumor inhibitors. Nucleosides & Nucleotides 1: 35-44, 1982.
7. Raghavan D, Bishop J, Sampson D, et al: Phase I and pharmacokinetic study of tiazofurin (NSC 286193) administered by 5-day continuous infusion. Cancer Chemother Pharmacol 16: 160-164, 1986.
8. Trump DL, Tutsch RD, Koeller JN, Tormey DC. Phase I clinical study with pharmacokinetic analysis of 2-β-D-ribofuranosyithiazole-4-carboxamide (NSC 286193) administered as a five day infusion. Cancer Res 45: 2853-2858, 1985.
9. Roberts JD, Stewart JA, McCormack JJ, et al. Phase I trial of tiazofurin administered by iv bolus daily for 5 days, with pharmacokinetic evaluation. Cancer Treat Rep 71: 141-149, 1987.
10. Balis FM, Lange BL, Packer RJ, et al: Pediatric phase I trial and pharmacokinetic study of tiazofurin (NSC 286193). Cancer Res 45: 5169-5172, 1985.
11. Melink TJ, Von Hoff DD, Kuhn JG, et al: Phase I evaluation of pharmacokinetics of tiazofurin (2-β-D-ribofuranosylthiazole-4-carboxamide. NSC 286193). Cancer Res 45: 2859-2865, 1985.